Early Detection Town Hall Meeting
Webinar Program
9 July 2008

Welcome
June Kinoshita, Executive Editor, Alzheimer Research Forum

Introductory remarks
Harold Varmus, M.D., President and CEO, Memorial Sloan-Kettering Cancer Center

About the Alzheimer's Study Group
Rob Egge, Center for Health Transformation

The strategic importance and challenges of early detection of AD
Sid Gilman, M.D., Director, Michigan Alzheimer's Disease Research Center

Early-stage and preclinical AD
John Morris, M.D., Director, Alzheimer's Disease Research Center, Washington University St. Louis

Imaging biomarkers for early detection of AD
Michael W. Weiner, M.D., Principal Investigator, Alzheimer's Disease Neuroimaging Initiative Director, Center for Imaging of Neurodegenerative Disease, VA Medical Center, San Francisco

Early detection of AD: fluid biomarkers
Anne Fagan, Ph.D., Research Associate Professor of Neurology, Washington University, St. Louis

Translating early detection to the clinic
Doug Galasko, M.D., Interim Director of UCSD Shiley-Marcos Alzheimer’s Disease Research Center

The role of clinical and research Centers of Excellence in early diagnosis
Rachelle Smith Doody, M.D., Ph.D., Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine

What pharma has/what pharma needs
Richard Mohs, PhD., Leader, Alzheimer's Disease Team, Eli Lilly and Company
Early detection of AD: The patient's and caregiver's perspective
Bill Bridgwater, patient advocate, National Board of Alzheimer's Association

Early detection and drug development: a brief overview
Paul Aisen, M.D., University of California, San Diego (UCSD) School of Medicine’s Department of Neurosciences, Director of the Alzheimer’s Disease Cooperative Study (ADCS)